Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025)
Vireo Growth (VREOF) reported Change in Accured Expenses of $10.1 million for Q4 2025, up 747.1% on a YoY basis from $1.2 million in Q4 2024, and up 154.18% sequentially from -$18.6 million in Q3 2025.
Vireo Growth (VREOF) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Change in Accured Expenses data on file, last reported at $10.1 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 747.1% year-over-year to $10.1 million; the trailing twelve-month figure through Dec 2025 stood at -$8.7 million (down 462.65% YoY), and the FY2025 full-year result was -$8.7 million, down 462.65% from the prior year.
- Change in Accured Expenses climbed to $10.1 million in Q4 2025, from -$18.6 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q4 2025 to a low of -$18.6 million in Q3 2025.
- A 5-year average of -$284488.8 and a median of $607847.0 in 2024 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 932.47% in 2025, while the deepest fall reached 797218.55% in 2025.
- Tracing VREOF's Change in Accured Expenses over 5 years: stood at $5.2 million in 2021, then slumped by 160.13% to -$3.1 million in 2022, then increased by 25.38% to -$2.3 million in 2023, then soared by 150.95% to $1.2 million in 2024, then surged by 747.1% to $10.1 million in 2025.
- Business Quant data shows VREOF's Change in Accured Expenses at $10.1 million in Q4 2025, -$18.6 million in Q3 2025, and -$2.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.08 Mn |
| Dec 31, 2025 | 10.08 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -1.99 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | -2,334.00 |
| Sep 30, 2024 | -2,334.00 |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 174,340.00 |
| Mar 31, 2024 | 174,340.00 |
| Dec 31, 2023 | -2.34 Mn |
| Dec 31, 2023 | -2.34 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |